Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
COSCIENS Biopharma Inc. (T.CSC) had Income from Continuous Operations of -2.51M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
-2.51M |
|
-- |
|
-- |
|
-- |
|
-3.20M |
|
-- |
|
-2.51M |
|
-2.51M |
|
-2.51M |
|
|
Income from Continuous Operations |
-2.51M |
-2.51M |
|
-2.51M |
|
-3.20M |
|
-2.80M |
|
3.18M |
|
3.18M |
|
-0.79 |
|
-0.79 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
32.87M |
|
-- |
|
-- |
|
-- |
|
25.87M |
|
7.00M |
|
7.00M |
|
7.00M |
|
3.18M |
|
| Cash Flow Statement Financials | |
-9.65M |
|
-0.91M |
|
-0.54M |
|
22.58M |
|
11.74M |
|
-10.84M |
|
-0.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.47 |
|
-- |
|
-- |
|
0.28 |
|
0.43 |
|
41.87% |
|
-156.64% |
|
-156.64% |
|
-- |
|
-122.66% |
|
-122.66% |
|
-10.55M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
0.49 |
|
0.92 |
|
97.40 |
|
-35.81% |
|
-35.81% |
|
-7.62% |
|
-25.84% |
|
2.20 |
|
-3.32 |
|
-3.04 |
|